Akari Therapeutics PLC (AKTX) – What Are Brokerages Saying About This Stock?

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $32.33.

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akari Therapeutics in a research note on Friday, October 2nd. Alliance Global Partners raised shares of Akari Therapeutics to a “strong-buy” rating in a report on Friday, September 18th. Wall Street Zen raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Finally, Maxim Group upgraded shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Monday, July 20th.

Akari Therapeutics Stock Down 7.5%

Shares of NASDAQ AKTX traded down $0.66 during trading hours on Friday, reaching $8.18. The stock had a trading volume of 21,683 shares, compared to its average volume of 50,568. The firm has a 50-day moving average of $9.16 and a 200-day moving average of $9.16. Akari Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $33.60.

About Akari Therapeutics

Akari Therapeutics, Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage.

Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan.